Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro‐adipogenic progenitors

Pharmacological treatment of Duchenne muscular dystrophy (DMD) with histone deacetylase inhibitors (HDACi) is currently being tested in clinical trials; however, pre‐clinical studies indicated that the beneficial effects of HDACi are restricted to early stages of disease. We show that FAPs from late...

Descripción completa

Detalles Bibliográficos
Autores principales: Consalvi, Silvia, Tucciarone, Luca, Macrì, Elisa, De Bardi, Marco, Picozza, Mario, Salvatori, Illari, Renzini, Alessandra, Valente, Sergio, Mai, Antonello, Moresi, Viviana, Puri, Pier Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171680/
https://www.ncbi.nlm.nih.gov/pubmed/35383427
http://dx.doi.org/10.15252/embr.202254721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171680/
https://www.ncbi.nlm.nih.gov/pubmed/35383427
http://dx.doi.org/10.15252/embr.202254721

Ejemplares similares